High expression of neuropeptide Y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8426-8433

  Körner, Meike ^a   Waser, Beatrice ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ARTICLE; AUTORADIOGRAPHY; CHEMODECTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; HUMANS; IODINE RADIOISOTOPES; NEUROBLASTOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGNOSIS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, NEUROPEPTIDE Y;

EID: 11144241787     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0821     Document Type: Article

References (39)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
2. Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-13.
3. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In Freeman LM, (ed): Nuclear Medicine Annual. New York: Raven Press; 1995. p. 1-50.
4. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996;125:26-34.
5. 90Y-DOTATOC. J Nucl Med 2002;43:610-6.
6. Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998;50:143-50.
7. Gehlert DR. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci 1994;55:551-62.
8. McDonald JK. Role of neuropeptide Y in reproductive function. Ann NY Acad Sci 1990;611:258-72.
9. Renshaw D, Hinson JP. Neuropeptide Y and the adrenal gland: a review. Peptides 2001;22:429-38.
10. Malendowicz LK, Markowska A, Zabel M. Neuropeptide Y-related peptides and hypothalamo-pituitary-adrenal axis function. Histol Histopathol 1996;11:485-94.
11. Nussdorfer GG, Mazzocchi G, Malendowicz LK. The possible involvement of pancreatic polypeptide in the paracrine regulation of human and rat adrenal cortex. Endocr Res 1998;24:695-702.
12. Bernet F, Maubert E, Bernard J, Montel V, Dupouy JP. In vitro steroidogenic effects of neuropeptide Y (NPY1-36), Y1 and Y2 receptor agonists (Leu31-Pro34 NPY, NPY18-36) and peptide YY (PYY) on rat adrenal capsule/zona glomerulosa. Regul Pept 1994;52:187-93.
13. Renshaw D, Thomson LM, Carroll M, Kapas S, Hinson JP. Actions of neuropeptide Y on the rat adrenal cortex. Endocrinology 2000;141:169-73.
14. Whitworth EJ, Kosti O, Renshaw D, Hinson JP. Adrenal neuropeptides: regulation and interaction with ACTH and other adrenal regulators. Microsc Res Tech 2003;61:259-67.
15. Reubi JC, Gugger M, Waser B, Schaer JC. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001;61:4636-41.
16. Körner M, Waser B, Reubi JC. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Investig 2004;84:71-80.
17. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. Washington DC: Armed Forces Institute of Pathology; 1997.
18. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001;127:143-55.
19. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Investig 1992;15:631-42.
20. Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. Ann NY Acad Sci 2002;970:54-60.
21. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-92.
22. Arola J, Liu J, Heikkila P, et al. Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm. J Endocrinol 2000;165:223-9.
23. Schwab M, Shimada H, Joshi V, Bradeur GM. Neuroblastic tumors of adrenal gland and sympathetic nervous system. In Kleihmes P, Cavence WK, (eds): World Health Organization classification of tumors. Pathology and genetics of tumors of the nervous system. Lyon, France: IARC Press; 2000. p. 153-61.
24. Li Q, Johansson H, Grimelius L. Innervation of human adrenal gland and adrenal cortical lesions. Virchows Arch 1999;435:580-9.
25. Hacker GW, Bishop AE, Terenghi G, et al. Multiple peptide production and presence of general neuroendocrine markers detected in 12 cases of human phaeochromocytoma and in mammalian adrenal glands. Virchows Arch A Pathol Anat Histopathol 1988;412:399-411.
26. 1 receptor antagonist: BIBP3226. Eur Pharmacol 1994;271:R11-3.
27. 2 receptor antagonist. Br J Pharmacol 2000;129:1075-88.
28. Cabrele C, Langer M, Bader R, et al. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem 2000;275:36043-8.
29. Whitcomb DC, Vigna SR, McVey DC, Taylor IL. Localization and characterization of pancreatic polypeptide receptors in rat adrenal glands. Am J Physiol 1992;262:G532-6.
30. Cavadas C, Silva AP, Mosimann F, et al. NPY regulates catecholamine secretion from human adrenal chromaffin cells. J Clin Endocrinol Metab 2001;86:5956-63.
31. Cohen PS, Cooper MJ, Helman LJ, et al. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 1990;50:6055-61.
32. Dotsch J, Christiansen H, Hanze J, Lampert F, Rascher W. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept 1998;75-76:185-90.
33. deS Senanayake P, Denker J, Bravo EL, Graham RM. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Investig 1995;96:2503-9.
34. Bjellerup P, Theodorsson E, Jornvall H, Kogner P. Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours. Br J Cancer 2000;83:171-6.
35. Reubi JC, Gugger M, Waser B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 2002;29:855-62.
36. Harrison LE, Gaudin PB, Brennan MF. Pathologic features Of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181-5.
37. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem 2001;44:1341-8.
38. Moertel CL, Reubi JC, Scheithauer BS, Schaid DJ, Kvols LK. Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol 1994;102:752-6.
39. 35S]GTPgammaS binding. J Chem Neuroanat 2003;26:179-93.